OptiNose (OPTN) - Total Assets
Based on the latest financial reports, OptiNose (OPTN) holds total assets worth $114.85 Million USD as of March 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore OptiNose (OPTN) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
OptiNose - Total Assets Trend (2015–2024)
This chart illustrates how OptiNose's total assets have evolved over time, based on quarterly financial data. See OPTN total equity for net asset value and shareholders' equity analysis.
OptiNose - Asset Composition Analysis
Current Asset Composition (December 2024)
OptiNose's total assets of $114.85 Million consist of 97.7% current assets and 2.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 65.6% |
| Accounts Receivable | $26.39 Million | 20.5% |
| Inventory | $11.46 Million | 8.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how OptiNose's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see OptiNose (OPTN) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: OptiNose's current assets represent 97.7% of total assets in 2024, a decrease from 98.8% in 2015.
- Cash Position: Cash and equivalents constituted 65.6% of total assets in 2024, down from 94.9% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2015.
- Asset Diversification: The largest asset category is accounts receivable at 20.5% of total assets.
OptiNose Competitors by Total Assets
Key competitors of OptiNose based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Almirall S.A.
MC:ALM
|
Spain | €2.36 Billion |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867
|
China | CN¥8.25 Billion |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436
|
China | CN¥1.41 Billion |
|
ANI Pharmaceuticals Inc
NASDAQ:ANIP
|
USA | $1.44 Billion |
|
North China Pharmaceutical Co Ltd
SHG:600812
|
China | CN¥21.45 Billion |
OptiNose - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.64 | 2.48 | 4.27 |
| Quick Ratio | 0.58 | 2.17 | 4.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-63.00 Million | $48.42 Million | $114.01 Million |
OptiNose - Advanced Valuation Insights
This section examines the relationship between OptiNose's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 24.26 |
| Latest Market Cap to Assets Ratio | 0.75 |
| Asset Growth Rate (YoY) | 19.5% |
| Total Assets | $128.78 Million |
| Market Capitalization | $97.22 Million USD |
Valuation Analysis
Below Book Valuation: The market values OptiNose's assets below their book value (0.75x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: OptiNose's assets grew by 19.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for OptiNose (2015–2024)
The table below shows the annual total assets of OptiNose from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $128.78 Million | +19.55% |
| 2023-12-31 | $107.73 Million | -25.30% |
| 2022-12-31 | $144.22 Million | -13.16% |
| 2021-12-31 | $166.07 Million | -12.04% |
| 2020-12-31 | $188.81 Million | +9.36% |
| 2019-12-31 | $172.65 Million | -20.43% |
| 2018-12-31 | $216.99 Million | -10.01% |
| 2017-12-31 | $241.14 Million | +480.34% |
| 2016-12-31 | $41.55 Million | +159.55% |
| 2015-12-31 | $16.01 Million | -- |
About OptiNose
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. It offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well … Read more